Tarsus Pharmaceuticals (TARS) Competitors $41.24 -0.31 (-0.73%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. GRFS, TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, PCVX, and CYTKShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors Grifols TG Therapeutics Nuvalent Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Tarsus Pharmaceuticals (NASDAQ:TARS) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability. Is TARS or GRFS more profitable? Grifols has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Grifols' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-44.91% -39.72% -25.74% Grifols N/A N/A N/A Do insiders and institutionals hold more shares of TARS or GRFS? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor TARS or GRFS? In the previous week, Tarsus Pharmaceuticals had 7 more articles in the media than Grifols. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 7 mentions for Grifols. Grifols' average media sentiment score of 0.46 beat Tarsus Pharmaceuticals' score of 0.30 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend TARS or GRFS? Tarsus Pharmaceuticals currently has a consensus price target of $66.67, suggesting a potential upside of 61.64%. Grifols has a consensus price target of $10.30, suggesting a potential upside of 2.33%. Given Tarsus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, TARS or GRFS? Grifols has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$233.67M7.42-$115.55M-$2.73-15.11Grifols$7.81B0.89$169.80M$1.178.60 Which has more volatility & risk, TARS or GRFS? Tarsus Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. SummaryGrifols beats Tarsus Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.73B$2.93B$5.50B$9.40BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-15.1120.2928.1319.86Price / Sales7.42259.75424.9198.68Price / CashN/A42.3835.5357.53Price / Book7.037.808.235.71Net Income-$115.55M-$55.11M$3.24B$257.80M7 Day Performance0.21%2.34%0.66%1.12%1 Month Performance4.63%13.02%8.07%11.30%1 Year Performance50.42%1.46%28.44%16.88% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals1.7787 of 5 stars$41.25-0.7%$66.67+61.6%+45.9%$1.73B$233.67M-15.1150News CoverageAnalyst RevisionGRFSGrifols3.5302 of 5 stars$9.72-0.2%$10.30+6.0%+23.8%$6.68B$7.81B8.3123,822Gap UpTGTXTG Therapeutics3.395 of 5 stars$38.92+5.0%$43.80+12.5%+72.5%$6.18B$329M162.17290NUVLNuvalent3.3386 of 5 stars$84.59+4.5%$119.60+41.4%+1.7%$6.07BN/A-19.2740LNTHLantheus4.5733 of 5 stars$83.06+2.2%$131.20+58.0%-37.1%$5.75B$1.53B23.60700News CoveragePositive NewsAnalyst ForecastRYTMRhythm Pharmaceuticals3.1599 of 5 stars$89.15+2.8%$91.00+2.1%+69.7%$5.67B$130.13M-31.73140Analyst RevisionAXSMAxsome Therapeutics4.6908 of 5 stars$112.33+3.1%$172.33+53.4%+31.0%$5.53B$385.69M-19.47380Analyst RevisionTLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/AAnalyst RevisionCRSPCRISPR Therapeutics3.264 of 5 stars$56.42-0.7%$71.75+27.2%-12.1%$4.87B$37.31M-12.48460Analyst RevisionPCVXVaxcyte1.7842 of 5 stars$36.38+1.3%$136.50+275.2%-56.1%$4.69BN/A-9.12160Positive NewsCYTKCytokinetics4.0491 of 5 stars$38.58+4.2%$70.92+83.8%-31.9%$4.61B$18.47M-7.29250Insider Trade Related Companies and Tools Related Companies Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Lantheus Alternatives Rhythm Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Alternatives CRISPR Therapeutics Alternatives Vaxcyte Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
